TSG Therapeutics
Singapore · Founded 2016
About TSG Therapeutics
TSG Therapeutics is a preclinical-stage biopharmaceutical company on a mission to eliminate viral infectious disease. TSG has designed a novel class of broad-spectrum antiviral drugs that are adaptable, scalable, and therapeutically effective against a wide range of emerging and re-emerging viruses. By utilizing disruptive approaches across engineering and medicine, we have developed a proven platform for developing drug candidates with potent antiviral activity against diverse classes of viruses. Whereas conventional approaches are based on a narrow “one bug, one drug” concept, our strategy is driven by a “one drug, many bugs” vision that will lead to clinical solutions for a wide range of viral infections and improve billions of lives around the world. TSG Therapeutics was established on April 1, 2016 by Will W. Park in Singapore, Central Region.
Company Facts
- Founded: 2016
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.6M
- Last round: Corporate Round (Jan 2023)
- Website: http://www.tsg-therapeutics.com/
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/tsg-therapeutics-175013 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.